Actively Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Led by Genentech, Inc. · Updated on 2026-05-04
120
Participants Needed
14
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
CONDITIONS
Official Title
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Diagnosis of relapsed or refractory multiple myeloma according to IMWG criteria
- Female participants of childbearing potential must agree to remain abstinent or use contraception
- Male participants must agree to remain abstinent or use a condom
You will not qualify if you...
- Prior treatment with cevostamab or another agent targeting FcRH5
- Prior treatment with elranatamab
- Prior allogeneic stem cell transplantation
- Absolute plasma cell count exceeding 500 per milliliter or 5% of peripheral blood white cells
- Diagnosis of Waldenström macroglobulinemia or POEMS syndrome
- Known history of amyloidosis
- History of autoimmune disease
- History of confirmed progressive multifocal leukoencephalopathy
- Peripheral motor polyneuropathy of prespecified grade
- Known or suspected chronic cytomegalovirus or Epstein-Barr virus infection
- Known history of hemophagocytic lymphohistiocytosis or macrophage activation syndrome
- Acute or chronic hepatitis B or hepatitis C infection
- HIV seropositivity
- History of central nervous system myeloma disease
- Significant cardiovascular disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
2
Calvary Mater Newcastle
Waratah, New South Wales, Australia, 2298
Actively Recruiting
3
Royal Adelaide Hospital;Haematology Clinical Trials Unit
Adelaide, South Australia, Australia, 5000
Actively Recruiting
4
St. Vincent's Hospital Melbourne
Melbourne, Victoria, Australia, 3065
Actively Recruiting
5
The Alfred Hospital
Prahan, Victoria, Australia, 3181
Actively Recruiting
6
The Chaim Sheba Medical Center - PPDS
Ramat Gan, Central District, Israel, 5262100
Actively Recruiting
7
Rambam Health Care Campus
Haifa, Israel, 3109600
Actively Recruiting
8
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel, 9112001
Actively Recruiting
9
Tel Aviv Sourasky Medical Center PPDS
Tel Aviv, Israel, 6423906
Actively Recruiting
10
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital)
Seocho, South Korea, 06591
Actively Recruiting
11
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
12
Severance Hospital, Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
13
Asan Medical Center.
Seoul, South Korea, 05505
Actively Recruiting
14
Samsung Medical Center - PPDS
Seoul, South Korea, 06351
Actively Recruiting
Research Team
G
GO43979 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here